The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of the PD-L1 inhibitor, durvalumab (MEDI4736; D) in combination with a PARP inhibitor, olaparib (O) or a VEGFR inhibitor, cediranib (C) in women's cancers (NCT02484404).
 
Jung-min Lee
No Relationships to Disclose
 
Alexandra Dos Santos Zimmer
No Relationships to Disclose
 
Stan Lipkowitz
No Relationships to Disclose
 
Christina M. Annunziata
No Relationships to Disclose
 
Tony Weishiu Ho
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Victoria L. Chiou
No Relationships to Disclose
 
Lori M. Minasian
No Relationships to Disclose
 
Nicole D. Houston
No Relationships to Disclose
 
Irene Ekwede
No Relationships to Disclose
 
Elise C. Kohn
No Relationships to Disclose